Medicare Payments for Newly Available Generic Drugs

摘要

The objectives are: (1) To estimate the financial impact of the two-quarter reimbursement lag on Medicare payments for Part B-covered drugs with newly available generic versions. (2) To estimate when high-expenditure brand-only Part B-covered drugs will likely have first-generic versions reach the market.